ArticleACS nano2025
Ascorbic Acid-Derived Supramolecular Gels Induce Immunogenic Ferroptosis in Cancer Cells to Potentiate Tumor Immunotherapy.
Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Covalent Organic Framework Bispecific Nanosystem for the Combined Treatment of Acute Myeloid Leukemia.Materials (Basel, Switzerland) · 2026Article
- Article
- Decoding the spatiotemporal characteristics of ferroptosis: reshaping tumour therapeutic strategies.Experimental hematology & oncology · 2026Review
- Recent Progress and Morphological Distribution of Polydopamine-Based Biomaterials and Their Applications.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-dose ascorbic acid (AA) therapy induces cancer cell death primarily through its oxidized derivative, dehydroascorbic acid (DHA). However, maintaining therapeutic AA concentrations within tumors and overcoming intratumoral hypoxia pose critical barriers to the clinical application of AA. Herein, we develop an injectable supramolecular gel (αPD-1@Lv/HPAGel) composed of ascorbyl palmitate (an AA derivative), lovastatin-loaded hemoglobin nanoparticles (Lv/Hb-PDA), and the immune checkpoint inhibitor anti-PD-1 (αPD-1). Upon intratumoral administration, this gel system sustains high local AA concentrations and promotes efficient oxidation of AA into DHA by alleviating hypoxia via the release of oxygen from hemoglobin. Simultaneously, lovastatin inhibits glutathione peroxidase 4, synergistically amplifying AA-induced ferroptosis. The coordinated induction of ferroptosis remodels the tumor immune microenvironment and stimulates a robust antitumor immune response. In combination with αPD-1, the gel system suppresses tumor growth and metastasis, establishes durable immune memory, and effectively prevents local and distant tumor recurrence postsurgery. Collectively, these findings present an approach for translating high-dose AA therapy into practice and provide evidence for the integration of ferroptosis induction with immunotherapy for enhanced cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.